tradingkey.logo
tradingkey.logo
Search

AstraZeneca PLC

AZN
Add to Watchlist
173.430USD
+4.980+2.96%
Market hours 10/22, 14:07(ET)
268.96BMarket Cap
25.87P/E TTM

AstraZeneca PLC (AZN) Revenue Performance

Updated: Jun 30, 2026

Last year, AstraZeneca PLC generated 8.40B USD for its biggest-performing segment, Farxiga. The United States made the largest contribution, accounting for 23.97B USD last year. For the latest quarter, AstraZeneca PLC reported the revenue of 61.02B USD for the period ending 2026-06-30, which came from the top-performing segment, Calquenc. United States contributed the highest revenue, at 6.68B USD.

By Business

Annual
Annual
Quarterly
Farxiga
Tagrisso
Imfinzi
Ultomiris
Calquenc
Lynparza
Symbicort
Fasenra
Soliris
Strensiq
Crestor
Breztri
Zoladex
Enhertu
Brilinta
Nexium
Truqap
Lokelma
Saphnelo
Koselugo
Seloken/Toprol-XL
BioPharmaceuticals: CVRM Others
Pulmicort
Tezspire
Oncology Others
Imjudo
Synagis
Beyfortus
BioPharmaceuticals: Respiratory & Immunology Others
Roxadustat
FluMist
rare disease - Other
Wainua
Airsupra
Other medicines others
Datroway
Vaccines & Immune Therapies Others
Andexxa
Kanuma
Orpathys
COVID-19 mAbs
Vaxzevria
Faslodex
Onglyza
Bydureon
Bevespi
Daliresp/Daxas Bevespi
Evusheld
Iressa
Arimidex
Casodex
Covid
Losec/Prilosec
Atacand
Seroquel XR/IR
Other diabetes
Byetta
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
Farxiga
8.40B(15.12%)
7.66B(15.03%)
5.96B(13.62%)
4.38B(10.19%)
3.00B(8.21%)
1.96B(7.57%)
Tagrisso
7.25B(13.05%)
6.58B(12.92%)
5.80B(13.24%)
5.44B(12.66%)
5.01B(13.72%)
4.33B(16.72%)
Imfinzi
6.06B(10.91%)
4.72B(9.26%)
4.24B(9.68%)
2.78B(6.47%)
2.41B(6.60%)
2.04B(7.89%)
Ultomiris
4.72B(8.49%)
3.92B(7.70%)
2.96B(6.77%)
1.97B(4.57%)
688.00M(1.88%)
--(--)
Calquenc
3.52B(6.33%)
3.13B(6.14%)
2.51B(5.74%)
2.06B(4.78%)
1.24B(3.39%)
522.00M(2.02%)
Lynparza
3.28B(5.90%)
3.07B(6.03%)
2.81B(6.42%)
2.64B(6.14%)
2.35B(6.43%)
1.78B(6.86%)
Symbicort
2.88B(5.19%)
2.88B(5.65%)
2.36B(5.39%)
2.54B(5.90%)
2.73B(7.47%)
2.72B(10.51%)
Fasenra
1.98B(3.56%)
1.69B(3.32%)
1.55B(3.55%)
1.40B(3.25%)
1.26B(3.44%)
949.00M(3.67%)
Soliris
1.84B(3.31%)
2.59B(5.08%)
3.15B(7.18%)
3.76B(8.75%)
1.87B(5.13%)
--(--)
Strensiq
1.68B(3.02%)
1.42B(2.78%)
1.15B(2.63%)
958.00M(2.23%)
378.00M(1.03%)
--(--)
Crestor
1.22B(2.19%)
1.15B(2.26%)
1.11B(2.53%)
1.05B(2.44%)
1.10B(3.00%)
1.18B(4.56%)
Breztri
1.20B(2.16%)
978.00M(1.92%)
677.00M(1.55%)
398.00M(0.93%)
203.00M(0.56%)
28.00M(0.11%)
Zoladex
1.11B(1.99%)
1.06B(2.08%)
952.00M(2.17%)
927.00M(2.16%)
948.00M(2.59%)
888.00M(3.43%)
Enhertu
977.00M(1.76%)
545.00M(1.07%)
261.00M(0.60%)
79.00M(0.18%)
17.00M(0.05%)
--(--)
Brilinta
823.00M(1.48%)
1.33B(2.62%)
1.32B(3.02%)
1.36B(3.16%)
1.47B(4.03%)
1.59B(6.15%)
Nexium
816.00M(1.47%)
867.00M(1.70%)
945.00M(2.16%)
1.28B(2.99%)
1.33B(3.63%)
1.49B(5.76%)
Truqap
728.00M(1.31%)
430.00M(0.84%)
6.00M(0.01%)
--(--)
--(--)
--(--)
Lokelma
698.00M(1.26%)
542.00M(1.06%)
412.00M(0.94%)
289.00M(0.67%)
175.00M(0.48%)
76.00M(0.29%)
Saphnelo
686.00M(1.23%)
467.00M(0.92%)
278.00M(0.63%)
116.00M(0.27%)
8.00M(0.02%)
--(--)
Koselugo
662.00M(1.19%)
531.00M(1.04%)
331.00M(0.76%)
208.00M(0.48%)
108.00M(0.30%)
38.00M(0.15%)
Seloken/Toprol-XL
607.00M(1.09%)
605.00M(1.19%)
640.00M(1.46%)
862.00M(2.00%)
951.00M(2.60%)
821.00M(3.17%)
BioPharmaceuticals: CVRM Others
534.00M(0.96%)
524.00M(1.03%)
296.00M(0.68%)
366.00M(0.85%)
196.00M(0.54%)
191.00M(0.74%)
Pulmicort
518.00M(0.93%)
682.00M(1.34%)
713.00M(1.63%)
645.00M(1.50%)
962.00M(2.63%)
996.00M(3.85%)
Tezspire
458.00M(0.82%)
248.00M(0.49%)
85.00M(0.19%)
4.00M(0.01%)
--(--)
--(--)
Oncology Others
425.00M(0.76%)
419.00M(0.82%)
224.00M(0.51%)
44.00M(0.10%)
50.00M(0.14%)
51.00M(0.20%)
Imjudo
346.00M(0.62%)
281.00M(0.55%)
--(--)
--(--)
--(--)
--(--)
Synagis
292.00M(0.53%)
447.00M(0.88%)
546.00M(1.25%)
578.00M(1.34%)
410.00M(1.12%)
372.00M(1.44%)
Beyfortus
281.00M(0.51%)
316.00M(0.62%)
106.00M(0.24%)
--(--)
--(--)
--(--)
BioPharmaceuticals: Respiratory & Immunology Others
274.00M(0.49%)
400.00M(0.79%)
324.00M(0.74%)
421.00M(0.98%)
594.00M(1.63%)
398.00M(1.54%)
Roxadustat
274.00M(0.49%)
331.00M(0.65%)
271.00M(0.62%)
197.00M(0.46%)
174.00M(0.48%)
--(--)
FluMist
272.00M(0.49%)
258.00M(0.51%)
216.00M(0.49%)
175.00M(0.41%)
253.00M(0.69%)
295.00M(1.14%)
rare disease - Other
231.00M(0.42%)
--(--)
--(--)
--(--)
--(--)
--(--)
Wainua
212.00M(0.38%)
85.00M(0.17%)
--(--)
--(--)
--(--)
--(--)
Airsupra
166.00M(0.30%)
66.00M(0.13%)
--(--)
--(--)
--(--)
--(--)
Other medicines others
156.00M(0.28%)
206.00M(0.40%)
231.00M(0.53%)
340.00M(0.79%)
106.00M(0.29%)
128.00M(0.49%)
Datroway
2.00M(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Vaccines & Immune Therapies Others
1.00M(--)
4.00M(0.01%)
--(--)
--(--)
--(--)
--(--)
Andexxa
--(--)
219.00M(0.43%)
182.00M(0.42%)
150.00M(0.35%)
68.00M(0.19%)
--(--)
Kanuma
--(--)
209.00M(0.41%)
171.00M(0.39%)
160.00M(0.37%)
62.00M(0.17%)
--(--)
Orpathys
--(--)
44.00M(0.09%)
44.00M(0.10%)
33.00M(0.08%)
16.00M(0.04%)
--(--)
COVID-19 mAbs
--(--)
31.00M(0.06%)
132.00M(0.30%)
--(--)
--(--)
--(--)
Vaxzevria
--(--)
4.00M(0.01%)
12.00M(0.03%)
1.80B(4.18%)
--(--)
--(--)
Faslodex
--(--)
--(--)
297.00M(0.68%)
334.00M(0.78%)
431.00M(1.18%)
580.00M(2.24%)
Onglyza
--(--)
--(--)
227.00M(0.52%)
257.00M(0.60%)
360.00M(0.99%)
470.00M(1.82%)
Bydureon
--(--)
--(--)
163.00M(0.37%)
280.00M(0.65%)
385.00M(1.05%)
448.00M(1.73%)
Bevespi
--(--)
--(--)
58.00M(0.13%)
58.00M(0.13%)
54.00M(0.15%)
48.00M(0.19%)
Daliresp/Daxas Bevespi
--(--)
--(--)
54.00M(0.12%)
189.00M(0.44%)
227.00M(0.62%)
217.00M(0.84%)
Evusheld
--(--)
--(--)
--(--)
2.19B(5.08%)
--(--)
--(--)
Iressa
--(--)
--(--)
--(--)
114.00M(0.27%)
183.00M(0.50%)
268.00M(1.04%)
Arimidex
--(--)
--(--)
--(--)
99.00M(0.23%)
139.00M(0.38%)
185.00M(0.71%)
Casodex
--(--)
--(--)
--(--)
78.00M(0.18%)
143.00M(0.39%)
172.00M(0.66%)
Covid
--(--)
--(--)
--(--)
--(--)
4.00B(10.95%)
--(--)
Losec/Prilosec
--(--)
--(--)
--(--)
--(--)
180.00M(0.49%)
183.00M(0.71%)
Atacand
--(--)
--(--)
--(--)
--(--)
97.00M(0.27%)
243.00M(0.94%)
Seroquel XR/IR
--(--)
--(--)
--(--)
--(--)
92.00M(0.25%)
117.00M(0.45%)
Other diabetes
--(--)
--(--)
--(--)
--(--)
59.00M(0.16%)
47.00M(0.18%)
Byetta
--(--)
--(--)
--(--)
--(--)
55.00M(0.15%)
68.00M(0.26%)

By Region

Annual
Annual
Quarterly
United States
China
United Kingdom
Other European Countries
Japan
Germany
Other Asia, Africa & Australasia
Central America/Other South American Countries
Sweden
France
Spain
Italy
Canada
Australia
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
United States
23.97B(40.81%)
21.81B(40.33%)
18.12B(39.56%)
17.28B(38.96%)
12.05B(32.20%)
8.96B(33.64%)
8.05B(33.00%)
China
6.64B(11.30%)
6.42B(11.87%)
5.87B(12.82%)
5.74B(12.95%)
6.00B(16.04%)
5.34B(20.08%)
4.87B(19.96%)
United Kingdom
4.36B(7.42%)
4.74B(8.77%)
3.37B(7.35%)
3.12B(7.03%)
3.25B(8.67%)
1.74B(6.54%)
1.82B(7.47%)
Other European Countries
4.32B(7.35%)
3.66B(6.77%)
3.11B(6.79%)
2.71B(6.10%)
1.95B(5.21%)
1.39B(5.23%)
1.29B(5.29%)
Japan
3.56B(6.05%)
3.45B(6.38%)
3.64B(7.95%)
3.99B(8.99%)
3.40B(9.07%)
2.57B(9.64%)
2.52B(10.34%)
Germany
2.89B(4.92%)
2.52B(4.67%)
2.10B(4.58%)
1.90B(4.29%)
1.49B(3.97%)
937.00M(3.52%)
704.00M(2.89%)
Other Asia, Africa & Australasia
2.72B(4.63%)
2.33B(4.31%)
2.04B(4.46%)
2.41B(5.42%)
2.38B(6.36%)
1.53B(5.76%)
1.42B(5.82%)
Central America/Other South American Countries
2.63B(4.48%)
2.25B(4.15%)
1.68B(3.67%)
1.18B(2.65%)
1.20B(3.22%)
761.00M(2.86%)
814.00M(3.34%)
Sweden
2.62B(4.47%)
2.29B(4.24%)
1.70B(3.72%)
1.72B(3.88%)
2.32B(6.21%)
1.03B(3.85%)
834.00M(3.42%)
France
1.41B(2.40%)
1.28B(2.37%)
1.15B(2.51%)
1.11B(2.50%)
915.00M(2.45%)
653.00M(2.45%)
578.00M(2.37%)
Spain
1.14B(1.93%)
994.00M(1.84%)
847.00M(1.85%)
738.00M(1.66%)
578.00M(1.54%)
398.00M(1.50%)
359.00M(1.47%)
Italy
1.08B(1.84%)
949.00M(1.76%)
813.00M(1.77%)
735.00M(1.66%)
577.00M(1.54%)
431.00M(1.62%)
396.00M(1.62%)
Canada
954.00M(1.62%)
937.00M(1.73%)
967.00M(2.11%)
1.17B(2.63%)
772.00M(2.06%)
596.00M(2.24%)
466.00M(1.91%)
Australia
454.00M(0.77%)
439.00M(0.81%)
390.00M(0.85%)
571.00M(1.29%)
547.00M(1.46%)
282.00M(1.06%)
266.00M(1.09%)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.